Scholarlink

Background <p>Empagliflozin, a member of the Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitor family, is a promising antidiabetic drug with proven benefits in heart failure (HF). However, its effects in heart failure patients in varying ejection fractions with and without diabetes, and its impact in a real-world clinical setting, remain underexplored.</p> Methods <p>This multicenter observational study, conducted in a real-world setting, from November 2022 to October 2023 in four specialized and tertiary care hospitals in Bangladesh. The study included 797 patients diagnosed with heart failure, irrespective of ejection fraction, who received empagliflozin at a dose of 10&#xa0;mg daily over six months. The primary aim was to evaluate the efficacy and safety of empagliflozin in enhancing clinical, biochemical, and echocardiographic parameters in patients with heart failure across ejection fraction types, with or without diabetes.</p> Results <p>Of the 797 enrolled patients, 460 (57.7%) had diabetes. Significant improvements were observed in both diabetic and non-diabetic groups across primary and secondary outcomes. Empagliflozin therapy led to improvements in New York Heart Association (NYHA) functional class (<i>p</i> = 0.001), echocardiographic parameters such as left ventricular ejection fraction (LVEF) (<i>p</i> = 0.003), and N-terminal pro–B-type Natriuretic Peptide (NT-proBNP) levels (<i>p</i> &lt; 0.001). Biochemical markers also showed positive changes, including a significant reduction in serum creatinine (<i>p</i> = 0.001) and improvements in estimated Glomerular Filtration Rate (eGFR) (<i>p</i> &lt; 0.001). Subgroup analyses revealed that the therapeutic effects were consistent across different age groups, BMI categories, and longer duration of diabetes.</p> Conclusions <p>Empagliflozin significantly improved cardiovascular and renal outcomes in heart failure patients, regardless of diabetes status. These findings support the inclusion of empagliflozin in the management of heart failure in clinical practice, particularly for patients with coexisting diabetes or chronic kidney disease. Further large-scale, long-term studies are needed to confirm these results and assess sustained benefits.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world insights into empagliflozin use in heart failure across ejection fractions and patients with or without diabetes: a multicenter study from Bangladesh

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月5日

查看全文
  • Shahjada Selim,
  • Md. Fakhrul Islam Khaled,
  • Dipal Krishna Adhikary,
  • Mir Jamal Uddin,
  • Abdul Wadud Chowdhury,
  • Saidur Rahman Khan,
  • A. K. M. Monwarul Islam,
  • Kazi Nazrul Islam,
  • Sujoy Kumar Saha,
  • Chayan Kumar Singha,
  • Md. Abu Bakar Siddique,
  • Chinmoy Saha,
  • Suraiya Rahman Shova,
  • Khondoker Md. Ferdoush Siraj,
  • Syed E. Shaude,
  • Sajal Krishna Banerjee

摘要

Background

Empagliflozin, a member of the Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitor family, is a promising antidiabetic drug with proven benefits in heart failure (HF). However, its effects in heart failure patients in varying ejection fractions with and without diabetes, and its impact in a real-world clinical setting, remain underexplored.

Methods

This multicenter observational study, conducted in a real-world setting, from November 2022 to October 2023 in four specialized and tertiary care hospitals in Bangladesh. The study included 797 patients diagnosed with heart failure, irrespective of ejection fraction, who received empagliflozin at a dose of 10 mg daily over six months. The primary aim was to evaluate the efficacy and safety of empagliflozin in enhancing clinical, biochemical, and echocardiographic parameters in patients with heart failure across ejection fraction types, with or without diabetes.

Results

Of the 797 enrolled patients, 460 (57.7%) had diabetes. Significant improvements were observed in both diabetic and non-diabetic groups across primary and secondary outcomes. Empagliflozin therapy led to improvements in New York Heart Association (NYHA) functional class (p = 0.001), echocardiographic parameters such as left ventricular ejection fraction (LVEF) (p = 0.003), and N-terminal pro–B-type Natriuretic Peptide (NT-proBNP) levels (p < 0.001). Biochemical markers also showed positive changes, including a significant reduction in serum creatinine (p = 0.001) and improvements in estimated Glomerular Filtration Rate (eGFR) (p < 0.001). Subgroup analyses revealed that the therapeutic effects were consistent across different age groups, BMI categories, and longer duration of diabetes.

Conclusions

Empagliflozin significantly improved cardiovascular and renal outcomes in heart failure patients, regardless of diabetes status. These findings support the inclusion of empagliflozin in the management of heart failure in clinical practice, particularly for patients with coexisting diabetes or chronic kidney disease. Further large-scale, long-term studies are needed to confirm these results and assess sustained benefits.

Clinical trial number

Not applicable.